Literature DB >> 2129506

Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.

M Lantz1, S Malik, M L Slevin, I Olsson.   

Abstract

Serum samples from cancer patients receiving intravenous infusions of recombinant tumor necrosis factor (rTNF) and recombinant interferon-gamma (rIFN-gamma) were analyzed for TNF and the TNF-binding protein (TNF-BP). TNF-BP is a soluble fragment of the transmembrane TNF receptor with antagonistic effects to TNF and is released by proteolytic cleavage of the receptor. During a 60-min infusion of rTNF, peak serum levels of rTNF were observed after 30 to 60 min and a transient increase of circulating TNF-BP was observed with peak levels between 30 and 120 min. Injection of IFN-gamma alone did not affect the levels of TNF and TNF-BP. Thus administration of rTNF leads to release into the circulation of TNF-BP, which may modulate both systemic and local effects of TNF and influence its therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129506     DOI: 10.1016/1043-4666(90)90048-x

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  47 in total

1.  Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo.

Authors:  R E Eliaz; D Wallach; J Kost
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman
Journal:  Cancer Res       Date:  2011-06-01       Impact factor: 12.701

3.  Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty.

Authors:  Kumral Ergun Cagli; Dursun Aras; Serkan Topaloglu; Bilal Geyik; Selime Ayaz; Goksel Cagirci; Halil Lutfi Kisacik; Sule Korkmaz
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 4.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

5.  Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.

Authors:  Akira Hachiya; Norimoto Kobayashi; Satoshi Matsuzaki; Yusuke Takeuchi; Yohei Akazawa; Tomonari Shigemura; Noriko Motoki; Junya Masumoto; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

6.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

7.  Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia.

Authors:  H Redl; G Schlag; G R Adolf; B Natmessnig; J Davies
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients.

Authors:  D Hober; S Benyoucef; A S Delannoy; D de Groote; F Ajana; Y Mouton; P Wattré
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

9.  Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor.

Authors:  A D Blann; C N McCollum
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

10.  Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I.

Authors:  C L Selinsky; K L Boroughs; W A Halsey; M D Howell
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.